These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34933328)

  • 1. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma.
    Delforge M; Shah N; Miguel JSF; Braverman J; Dhanda DS; Shi L; Guo S; Yu P; Liao W; Campbell TB; Munshi NC
    Blood Adv; 2022 Feb; 6(4):1309-1318. PubMed ID: 34933328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
    Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
    Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.
    McGarvey N; Ung B; Carattini T; Imanak K; Lee A; Campbell TB; Patwardhan P
    Adv Ther; 2023 Oct; 40(10):4626-4638. PubMed ID: 37597153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
    Delforge M; Otero PR; Shah N; Moshkovich O; Braverman J; Dhanda DS; Lanar S; Devlen J; Miera M; Gerould H; Campbell TB; Munshi NC
    Leuk Res; 2023 Jun; 129():107074. PubMed ID: 37087950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study.
    Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D
    Transplant Cell Ther; 2024 Jun; 30(6):630.e1-630.e8. PubMed ID: 38458477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma.
    Minakata D; Ishida T; Ando K; Suzuki R; Tanaka J; Hagiwara S; Ananthakrishnan R; Kuwayama S; Nishio M; Kanda Y; Suzuki K
    Int J Hematol; 2023 May; 117(5):729-737. PubMed ID: 36690910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
    Anderson LD
    Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial.
    Shah N; Delforge M; San-Miguel J; Moshkovich O; Braverman J; Dhanda DS; Lanar S; Miera M; Williams A; Murphy R; Devlen J; Hege K; Campbell TB; Munshi NC
    Leuk Res; 2022 Sep; 120():106921. PubMed ID: 35930999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France.
    Karampampa K; Zhang W; Venkatachalam M; Cotte FE; Dhanda D
    J Med Econ; 2023; 26(1):243-253. PubMed ID: 36705644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
    Martin T; Usmani SZ; Schecter JM; Vogel M; Jackson CC; Deraedt W; Tian H; Yeh TM; Banerjee A; Pacaud L; Garrett A; Haltner A; Cameron C; Van Sanden S; Diels J; Valluri S; Samjoo IA
    Curr Med Res Opin; 2021 Oct; 37(10):1779-1788. PubMed ID: 34256668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma.
    Shah N; Mojebi A; Ayers D; Cope S; Dhanasiri S; Davies FE; Hari P; Patel P; Hege K; Dhanda D
    J Comp Eff Res; 2022 Jul; 11(10):737-749. PubMed ID: 35485211
    [No Abstract]   [Full Text] [Related]  

  • 12. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
    Rodriguez-Otero P; Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R; Bahlis NJ; Moreau P; Solomon SR; Delforge M; Berdeja J; Truppel-Hartmann A; Yang Z; Favre-Kontula L; Wu F; Piasecki J; Cook M; Giralt S
    N Engl J Med; 2023 Mar; 388(11):1002-1014. PubMed ID: 36762851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma.
    Jagannath S; Lin Y; Goldschmidt H; Reece D; Nooka A; Senin A; Rodriguez-Otero P; Powles R; Matsue K; Shah N; Anderson LD; Streetly M; Wilson K; Le HV; Swern AS; Agarwal A; Siegel DS
    Blood Cancer J; 2021 Jun; 11(6):116. PubMed ID: 34145225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients.
    Sanoyan DA; Seipel K; Bacher U; Kronig MN; Porret N; Wiedemann G; Daskalakis M; Pabst T
    BMC Cancer; 2023 Apr; 23(1):345. PubMed ID: 37061680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
    Munshi NC; Anderson LD; Shah N; Madduri D; Berdeja J; Lonial S; Raje N; Lin Y; Siegel D; Oriol A; Moreau P; Yakoub-Agha I; Delforge M; Cavo M; Einsele H; Goldschmidt H; Weisel K; Rambaldi A; Reece D; Petrocca F; Massaro M; Connarn JN; Kaiser S; Patel P; Huang L; Campbell TB; Hege K; San-Miguel J
    N Engl J Med; 2021 Feb; 384(8):705-716. PubMed ID: 33626253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma.
    Martin T; Jackson CC; Pacaud L; Madduri D; Jagannath S
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):22-27. PubMed ID: 36411210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
    Rodriguez-Otero P; Ayers D; Cope S; Davies FE; Delforge M; Mojebi A; Jansen JP; Weisel K; Hege K; Dhanasiri S
    Leuk Lymphoma; 2021 Oct; 62(10):2482-2491. PubMed ID: 33896344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
    Martin T; Lin Y; Agha M; Cohen AD; Htut M; Stewart AK; Hari P; Berdeja JG; Usmani SZ; Yeh TM; Olyslager Y; Goldberg JD; Schecter JM; Madduri D; Jackson CC; Deraedt W; Gries KS; Fastenau JM; Trudeau JJ; Akram M; Pacaud L; Jakubowiak A; Jagannath S
    Lancet Haematol; 2022 Dec; 9(12):e897-e905. PubMed ID: 36215989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
    Hansen DK; Sidana S; Peres LC; Colin Leitzinger C; Shune L; Shrewsbury A; Gonzalez R; Sborov DW; Wagner C; Dima D; Hashmi H; Kocoglu MH; Atrash S; Simmons G; Kalariya N; Ferreri C; Afrough A; Kansagra A; Voorhees P; Baz R; Khouri J; Alsina M; McGuirk J; Locke FL; Patel KK
    J Clin Oncol; 2023 Apr; 41(11):2087-2097. PubMed ID: 36623248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.
    Lee DH; Kumar A; Mohammed T; Peres LC; Alsina M; Bachmeier C; Blue BJ; Brayer J; Chandrasekhar S; Grajales Cruz A; De Avila G; Elmariah H; Faramand R; Freeman C; Jain M; Khadka S; Khimani F; Liu H; Nishihori T; Oswald LB; Castaneda Puglianini OA; Shain KH; Smith E; Baz RC; Locke FL; Oliveira GH; Alomar M; Hansen DK
    Blood Adv; 2023 Aug; 7(16):4247-4257. PubMed ID: 37307173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.